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The origin of Ewing’s sarcoma is a subject of much debate. Once thought to be derived from primitive neuroectodermal cells,
many now believe it to arise from a mesenchymal stem cell (MSC). Expression of the EWS-FLI1 fusion gene in MSCs changes cell
morphology to resemble Ewing’s sarcoma and induces expression of neuroectodermal markers. In murine cells, transformation
to sarcomas can occur. In knockdown experiments, Ewing’s sarcoma cells develop characteristics of MSCs and the ability to
diﬀerentiate into mesodermal lineages. However, it cannot be concluded that MSCs are the cell of origin. The concept of an MSC
still needs to be rigorously deﬁned, and there may be diﬀerent subpopulations of mesenchymal pluripotential cells. Furthermore,
EWS-FLI1 by itself does not transform human cells, and cooperating mutations appear to be necessary. Therefore, while it is
possible that Ewing’s sarcoma may originate from a primitive mesenchymal cell, the idea needs to be reﬁned further.
1.Introduction
Ewing’s sarcoma is a rare malignancy primarily aﬀecting
children and adolescents. It arises mainly in bone and less
commonly in soft tissues. The poorly diﬀerentiated tumors
are aggressive and metastasize early to lung, bone marrow,
and other tissues [1–4]. In all cases of the disease, there
is a characteristic reciprocal chromosomal translocation,
which leads to an in-frame fusion between the EWS gene
and one of the ETS family gene members [5, 6]. In
approximately 85% of cases, the EWS gene is combined with
the ETS gene FLI1 in a t(11;22) translocation. In about
10% of cases, EWS is fused to ERG, which has a high
degree of homology with FLI1 in the carboxyl terminus.
In very rare cases, EWS is fused to other ETS family
genes such as FEV and ETV1 [1, 7]. The EWS-ETS fusion
gene appears to be critically important for maintaining
the tumor phenotype of the disease. Ewing’s sarcoma cells
with EWS-FLI1 knockdown by siRNA exhibit decreased
cell proliferation, and tumor xenografts regress in mice [8,
9].
2. Mechanism for EWS-FLI1 in Tumorigenesis
The mechanism by which EWS-FLI1 contributes to tumori-
genesis is complex since the gene aﬀects the cell in many
diﬀerent ways. The best known function of the EWS-FLI1
protein is that of an aberrant transcription factor [10]. Its
structure consists of an N-terminal EWS transcriptional acti-
vationdomainandaC-terminalFLI1DNA-bindingdomain.
Disruption of either domain impairs the transformation
activity of the protein [11, 12].
EWS-FLI1 possesses the winged helix-turn-helix motif of
the ETS family of transcription factors, and EWS-FLI1 rec-
ognizes the same consensus DNA binding sequence as FLI1.
However, because of aberrant protein-protein interactions,
in large part due to the EWS portion of the molecule, EWS-
FLI1 has an altered proﬁle of gene regulation. It is relevant to
note that FLI1 can act as an oncogene in its own right. Fli1
(Friend leukemia virus integration) was originally identiﬁed
as the gene activated by insertion of the Friend murine
leukemia virus (MuLV) [13]. It has the capacity to transform
murine cells and is responsible for the development of2 Sarcoma
erythroleukemias in mice [14]. It is presumably the fusion
of the N-terminal moiety of EWS that confers the ability to
induce Ewing’s sarcoma in human cells.
Acting as either a transcriptional activator or repressor,
EWS-FLI1 regulates a number of important target genes.
EWS-FLI1 has been found to upregulate genes that promote
cell survival and proliferation, including IGF1 [15], Myc
[16], TOPK [17], NKX2.2 [18], ID2 [19], DAX1 [20], GLI1
[21], EZH2 [22], MK-STYX [23], and PLD2 [24]. EWS-FLI1
concomitantly represses genes that induce cell cycle arrest
and apoptosis, including TGFB2 [25], p21 [26], p57kip [27],
and IGFBP3 [28]. Interestingly, EWS-FLI1 also upregulates
genes that are involved in cell diﬀerentiation such as SOX2
[29]a n dEZH2 [22].
While progress has been made in characterizing the
downstream targets of EWS-FLI1, the properties of EWS-
FLI1maynotbefullyexplainedonthebasisofitsactivityasa
transcription factor. There are other properties of EWS-FLI1
thathave not been studied quiteso extensively. These include
RNA binding, RNA splicing and protein-protein interactions
[30–37]. Furthermore, it has become increasingly clear
that the cellular context has a large bearing upon the
transformationprocess.EarlyexperimentswithEWS-FLI1 in
NIH3T3 cells were somewhat artiﬁcial in the sense that these
cells were immortalized murine ﬁbroblasts. Paradoxically, in
normal murine and human ﬁbroblasts, EWS-FLI1 by itself
does not transform cells; instead, it results in cell cycle arrest
[38, 39]. These ﬁndings suggest the possibility that EWS-
FLI1mayhavecomplexantagonisticeﬀectsondiﬀerenttypes
of cells and underscore the importance of identifying the
correct cell of origin for the disease.
3. PrimitiveNeuroectodermalFeaturesof
Ewing’s Sarcoma
The origin of Ewing’s sarcoma is a controversial topic [7].
Histologically, Ewing’s sarcoma has a certain resemblance
to primitive neuroectodermal cells, and it was once widely
believed that the tumor arose from such cells [40, 41]. Early
neural markers, such as neuron-speciﬁc enolase (NSE) and
S-100, are present in some tumors [42, 43]. Ultrastructural
features, such as neurosecretory granules, can also be
observed with electron microscopy in some cases as well [41,
43].LaboratoryexperimentshavedemonstratedthatEwing’s
sarcoma cells can be induced to diﬀerentiate towards the
neural lineage in vitro and acquire neuritic processes under
appropriate stimulation [44]. Conversely, introduction of
EWS-FLI1 into neuroblastoma cell lines has been shown to
make the cells less diﬀerentiated and acquire characteristics
of Ewing’s sarcoma [45].
In spite of considerable data pointing to a neuroecto-
dermal origin, some doubt has been cast upon this idea.
The neural markers seen in Ewing’s sarcoma are present
only in a minority of cases, and even in such tumors, they
occur sporadically in cells. More importantly, EWS-FLI1 has
been shown to induce neuroectodermal diﬀerentiation and
upregulate a number of genes associated with early neural
diﬀerentiation [46, 47]. The ﬁndings raise the possibility
that the neuroectodermal characteristics of Ewing’s sarcoma
might be a direct result of EWS-FLI1 expression and not
necessarily the cell of origin.
4.Mesenchymal StemCells
An alternative hypothesis is that Ewing’s sarcoma derives
fromamesenchymalstemcell.Thisaddressesonesimplebut
nagging question regarding the neuroectodermal theory of
histogenesis, namely, whether bone normally contains prim-
itive neuroectodermal cells. While cranial bones develop
from mesenchymal condensation of neuroectoderm [48],
the long bones of the limbs originate from mesoderm [49],
and there may not normally be primitive neuroectodermal
cells in bone. Since most cases of Ewing’s sarcoma arise in
bone, it seems plausible that the cell of origin ought to be
a normal resident of bone. It may be signiﬁcant to note
that mesenchymal cells in bone marrow can exhibit some
characteristics of neuroectodermal cells [48, 50]. The cells
sometimes express neural markers spontaneously, including
S-100 and neuroﬁlament M [50]. They can also be induced
in vitro to diﬀerentiate towards the neural lineage [51, 52].
A fundamental problem with the mesenchymal hypothe-
sis is that one must deﬁne what exactly constitutes a “mes-
enchymal stem cell.” The term is widely used in scientiﬁc
literature, and yet the existence of the cell has not been
rigorously proven or deﬁned [53]. The term MSC usually
implies a bone marrow-derived cell that has the capacity to
diﬀerentiate towards various mesodermal lineages, such as
osteoblasts, chondrocytes, and adipocytes. In order to satisfy
the criteria for being a stem cell, it must be shown to be (1)
self-renewing and (2) able to generate diﬀerent tissue types
in vivo from a single cell. This has proven to be a daunting
task, and perhaps as a result, the putative MSC has yet to
be deﬁned in terms of a reliable set of cell surface markers
that would aid greatly in consistent extraction of the cells
[54] .C e l l sc o n s i d e r e dt ob eM S C sh a v eb e e nr e p o r t e dt ob e
positive for a number of markers, including Sca-1, Stro-1,
SH2, SH3, SH4, CD29, CD44, CD90, and CD105, but none
of these are entirely speciﬁc for MSCs [53–58].
MostpreparationsofMSCsareheterogeneous[59].Bone
marrow extracts are typically plated on plastic dishes, and
the adherent cells are enriched for cells that have some
of the desired properties of MSCs. However, the cultures
contain a mixture of cells, including hematopoietic stem
cells, endothelial cells, osteoblasts, and other cells. The
cells can be stimulated to undergo diﬀerentiation towards
osteoblastic, chondroblastic, and adipocytic lineages in vitro
underappropriatecultureconditions.Onenotesthoughthat
unless cultures are derived from single cell colonies, it is
possible that diﬀerent cell subpopulations diﬀerentiate into
the various lineages, and it is therefore not accurate to call
the cells MSCs. Furthermore, expression of in vitro markers
of diﬀerentiation does not equate to the capacity for in vivo
diﬀerentiation [53]. For these reasons, some authors prefer
to call these cell preparations by less presumptive terms, such
as “bone marrow stromal cells” as opposed to MSCs.
There are data to support the idea that there is more than
one type of pluripotential nonhematopoietic cell in bone
marrow. Colter et al. showed that within the population ofSarcoma 3
plasticadherentcells,thereareatleasttwodistinctsubgroups
which could be separated on the basis of size and cell surface
markers [60]. A small, round cell with rapid doubling time
seems to predominate at early passage whereas a larger
spindle cell tends to divide more rapidly at later times. The
latter cell type may be an osteoblast precursor and perhaps
less pluripotential since it spontaneously expresses alkaline
phosphatase, an osteoblast marker.
Jiang et al. showed that bone marrow contains a
small population of pluripotential cells, which they termed
“marrow-associated progenitor cells” (MAPCs) [61]. The
cells represent a subset of the bone marrow cells that
adhere to plastic. The cells were found to have clonogenic
self-renewal capabilities. Furthermore, when injected into
blastocysts, the cells developed into many diﬀerent tissues,
including those derived from ectoderm, endoderm, and
mesoderm. These cells may be distinct from the majority of
cells typically termed MSCs since their cell surface markers
appear to be diﬀerent from most of the plastic-adherent cells
extracted from bone marrow.
At the present time, it should be recognized that our
understanding of the “mesenchymal stem cell” is far from
complete. The exact nature and composition of the majority
of plastic-adherent bone marrow cells is still in question. The
very primitive stem cell described by Jiang et al. [61]m a yb e
similar to the stem cells found in other tissues [62]a n dm a y
not represent the more prevalent bone marrow stromal cell.
Within the latter group of cells, there may be multiple sub-
populations of cell types with varying pluripotential capabil-
ities for in vivo diﬀerentiation, analogous to hematopoietic
cells [54].
5. MSC Characteristics of Ewing’s Sarcoma
There are several lines of evidence that support the notion
that Ewing’s sarcoma is derived from an MSC-like cell
(accepting for the moment the concept of the MSC).
Using Ewing’s sarcoma cell lines, researchers have knocked
down the expression of EWS-FLI1 and shown that the
c e l l sh a v es o m ec a p a c i t yf o rin vitro diﬀerentiation towards
chondroblastic, osteoblastic, and adipocytic lineages [63].
Several groups have demonstrated that expression of EWS-
FLI1 in murine MSCs resulted in transformation of the cells,
and when these cells were implanted into mice, sarcomas
formed [64, 65] .T h et u m o r ss h a r e ds o m ec h a r a c t e r i s t i c s
with Ewing’s sarcoma, including cell surface markers and cell
morphology. In a related set of experiments, expression of
EWS-FLI1 in the pluripotential murine cell line C3H10T1/2
inhibited the cells ability to diﬀerentiate into osteoblasts
and adipocytes while upregulating neural genes [66]. When
injected into mice, these cells formed metastatic sarcomas.
In contrast to the mouse studies, human MSCs that were
infected with a retrovirus containing EWS-FLI1 failed to
form tumors when injected into immunodeﬁcient mice [67].
Although somewhat disappointing, the results are not at all
surprising since it has been reported that transformation
of normal human mesenchymal cells requires multiple
mutations [68]. Murine mesenchymal cells are more apt to
transform spontaneously in culture and form sarcomas [69].
It is worthwhile to note that human cells expressing EWS-
FLI1 take on a rounded morphology and express some of the
neuroectodermal markers seen in Ewing’s sarcoma [67, 70].
Furthermore, the expression of CD99, a relatively speciﬁc
marker for Ewing’s sarcoma, was found to be present at a
low level in MSCs and upregulated by EWS-FLI1 [67]. This
addressed a previously raised concern against the theory of
an MSC origin of Ewing’s sarcoma regarding expression of
CD99 in MSCs [71].
The relationship between Ewing’s sarcoma and human
mesodermal cells has been strengthened further in other
experiments. Ewing’s sarcoma cell lines with knockdown
of EWS-FLI1 have a transcription proﬁle similar to that of
the human fetal ﬁbroblast cell line IMR-90 [75]. Similarly,
Tirode et al. showed that in an EWS-FLI1 knock-down
experiment, the gene expression proﬁle of the cells began
to converge upon that of mesenchymal stem cells [63]. This
was statistically signiﬁcant for the subset of genes that were
upregulated or downregulated by EWS-FLI1, but it is note-
worthy that the overall pattern of gene expression appeared
to have distinct diﬀerences between MSCs and Ewing’s
sarcoma cells with EWS-FLI1 knockdown. Comparison of
cell surface markers has also shown some similarities and
diﬀerences between MSCs and Ewing’s sarcoma (Table 1).
A complementary set of observations was made by Burns
et al., who reported that late passage human mesenchymal
cells that spontaneously transformed after introduction of
telomerase(hMSC-TERT20)tookonanimmunohistochem-
ical proﬁle that was reminiscent of Ewing’s sarcoma, namely,
CD99+, vimentin+, CD45−,c y t o k e r a t i n −, and desmin−
[72]. Finally, in a meta-analysis of studies on genes aﬀected
by EWS-FLI1,a“ c o r eEWS-FLI1 transcriptional signature”
was identiﬁed which shared similarities with published
mesenchymal stem cell data [76]. While these collective data
are supportive of a mesenchymal origin of Ewing’s sarcoma,
it is clear that simple knock-down of EWS-FLI1 in tumor
cells does not cause them to revert to a normal mesenchymal
cell. Other changes have accumulated in the cells that make
them distinctly diﬀerent from recognizable normal cells.
6.Knock-in andTransgenic Mouse Models
The importance of cellular context has been highlighted
in recent mouse models. Several knock-in and transgenic
mice expressing EWS-FLI1 have now been created. In all of
these models, a strategy of conditional expression has been
employed to avoid lethal eﬀects of EWS-FLI1. Constitutive
expression of EWS-FLI1 protein in embryonic stem cells
causes cell death [77], and mice with expression of EWS-
FLI1 in the whole body have an embryonic lethal phenotype
[78, 79]. To circumvent this problem, investigators have used
cre-loxP recombination to achieve conditional expression of
the protein in vivo. Tissue-speciﬁc cre transgenic mice are
crossed to the EWS-FLI1 mice to restrict expression of the
protein to certain tissues or cells.
Torchia et al. developed a knock-in EWS-FLI1 mouse
at the Rosa26 locus [78]. When EWS-FLI1 was expressed
by use of the Mx1-cre mouse, myeloid/erythroid leukemias
developed. These malignancies were similar to but distinct4 Sarcoma
Table 1: Cell surface marker analysis of mesenchymal cells and Ewing’s sarcoma.
M a r k e r M e s .C e l l s M e s .C e l l s+E W S - F L I 1 E S F T ESFT + EWS-FLI1
knockdown Refs.
CD10 + −− [70]
CD13 + −− [70]
CD29 + − +[ 63]
CD44 + + − +[ 57, 63, 70]
CD45 (leukocyte
common antigen)
−− [57, 72]
CD54 ∓ + ∓ +[ 63, 70]
CD59 + − +[ 63]
CD73 + − +[ 63]
CD99 (MIC2) ∓ ++ + + [ 67, 70, 71, 73]
CD105 + + ∓ +[ 57, 63, 70]
CD 117 (c-kit) − ++ [ 70]
CD166 + + + + [63, 70]
CD271 − ++ [ 70]
Vimentin + + [72]
Caveolin-1 + + [73, 74]
Desmin −− [72]
Cytokeratin −− [72]
Mes. cells: human bone marrow-derived mesenchymal cells.
ESFT: Ewing’s sarcoma family of tumors.
∓ indicates weak or variable staining.
from the erythroleukemias induced by F-MuLV. The Mx1-
cre mouse expresses cre recombinase in the liver, spleen,
bone marrow, and lymphoid tissues after induction with
alpha/beta interferon or polyinosinic∗poly(C) (pIpC) [80].
While the original strategy was to target expression to
bone marrow progenitor cells, it is likely that the gene was
preferentiallyexpressedinhematopoieticprecursors,thereby
producing leukemias.
Codrington et al. developed an interesting Ews-ERG
mouse, which possesses an inverted ERG cassette ﬂanked by
loxP sites in intron 8 of the Ews gene, to simulate the t(21;22)
translocation that produces the EWS-ERG fusion [81]. They
obtainedTcelllymphomasinallmicebutthismayhavebeen
duetotheirchoiceoftheRag1-cremouse,whichexpressescre
recombinase in lymphocytes only [82].
Although it may be somewhat surprising that leukemias
and lymphomas were found in the previous two mouse
models, there is reason to believe that this has clinical
relevance to human disease. While it was once believed
that EWS-FLI1 was speciﬁc to Ewing’s sarcoma, it is now
known that EWS-FLI1 and related EWS-ETS fusions occur
sporadically in other malignancies, including leukemias [83–
87] and biphenotypic tumors, which have features of both
myogenic and neuroectodermal diﬀerentiation [88]. These
cases indicate that EWS-FLI1 can potentially contribute to
neoplastic growth outside of the typical cellular context in
which Ewing’s sarcoma arises. Quite interestingly, the CD99
marker, which is commonly used for immunohistochemical
testing for Ewing’s sarcoma, is actually considered a normal
leukocyte marker and is uniformly expressed on thymocytes
[89].
In a diﬀerent transgenic mouse model of EWS-FLI1,
conditional expression of the fusion protein was achieved
in the mesoderm-derived tissues of the limbs by crossing
to the Prx1-cre mouse, which expresses cre in the primitive
mesenchyme of the early limb bud [79]. Part of the rationale
behind this cross was to spare the hematopoietic cells and
thereby increase the likelihood of inducing sarcomas. Limb
shortening, muscle atrophy, osseous dysplasia, and other
developmental abnormalities were observed, reinforcing
the idea that EWS-FLI1 impairs growth and diﬀerentia-
tion of cells. However, in this model, sarcomas did not
spontaneously form unless the p53 gene was simultane-
ously mutated [79]. In contrast to the more diﬀerentiated
osteosarcomas that formed without EWS-FLI1 in mice with
conditional mutation of p53 induced by Prx1-cre, the tumors
that arose with EWS-FLI1 were undiﬀerentiated sarcomas,
similar to Ewing’s sarcoma.
Although concern has been raised regarding the validity
of mouse models for Ewing’s sarcoma [76], the transgenic
mouse model employing Prx1-cre does underscore one
important feature of Ewing’s sarcoma, namely, that EWS-
FLI1 alone does not appear to be suﬃcient to confer
sarcomatous change in an in vivo setting. Similar to the
results obtained with human MSCs expressing EWS-FLI1,
additional cooperating mutations seem to be required for
transformation to occur. The nature and timing of these
mutations may be an interesting subject for future researchSarcoma 5
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Figure 1: Cooperative mutations in the development of Ewing’s
sarcoma. (a) A t(11;22) reciprocal translocation produces the
EWS-FLI1 gene, but this tends to cause growth arrest in normal
cells. (b) A mutation randomly occurring prior to the t(11;22)
translocation might cooperate with EWS-FLI1 to permit escape
from growth arrest (or even promote cell proliferation) and
subsequent transformation to Ewing’s sarcoma. (c) The cooperative
mutation may occur after the t(11;22) translocation; this would
necessarilyimplyamechanismforcontinuedcellgrowthafterEWS-
FLI1 is expressed.
(Figure 1). The limb shortening of transgenic mice [79]a n d
experimental cell culture work of various groups [39, 50]
suggest that EWS-FLI1 impairs growth of normal cells, and
this may be problematic in envisioning a pathway for neo-
plastic transformation to occur. While many have postulated
that mutations occur after the t(11;22) translocation event, it
is also possible that EWS-FLI1 transforms a cell that carries a
silent but critical mutation in another gene.
The requirement for additional mutational events has
precedent in other mouse models. For example, in a knock-
in model of alveolar rhabdomyosarcoma, mutations in
Ink4A/Arf or Trp53 were needed for the Pax3;Fkhr fusion
to transform cells eﬀectively [90]. Interestingly, conditional
expression in the correct cell of origin—postnatal diﬀer-
entiating myoﬁbers—was also found to be important for
rhabdomyosarcomas to develop in this particular model.
TRP53, however, is unlikely to be the critical cooperating
mutated gene in Ewing’s sarcoma since TRP53 mutations are
found only in about 10% of Ewing’s sarcoma cases [91].
7. Conclusions
Identiﬁcation of the correct cell of origin is crucial to the
understanding of Ewing’s sarcoma. While there has been
steadily accumulating evidence that the cell of origin may be
a primitive pluripotential cell that resides in bone marrow,
one cannot state unequivocally that it is either a neuroec-
todermal cell or a “mesenchymal stem cell.” One important
simple reason for this is that the concept of the MSC has
yet to be rigorously deﬁned, and the term is used somewhat
loosely in the scientiﬁc literature. MSCs, as they are typically
prepared, are composed of a mixture of diﬀerent cells, and
some of these do exhibit neuroectodermal properties. It is
possible that a subpopulation of the pluripotential cells in
bone marrow is especially vulnerable to the transforming
eﬀects of EWS-FLI1.
Even if the correct cell of origin can be identiﬁed with
precision, much has yet to be learned. Expression of EWS-
FLI1 alone is not suﬃcient for transformation of normal
humancells.Instead,EWS-FLI1 tendstocausegrowtharrest.
In the early excitement over the discovery of EWS-FLI1,
researchersfocusedlargelyupondownstreamtranscriptional
targets. Current research suggests that there may be critically
important cooperating mutations that work in concert with
EWS-FLI1. The “cell of origin” concept may be a simplistic
one in that it might not be a normal cell from which Ewing’s
sarcoma arises. EWS-FLI1 may be fully transforming only in
a mutated cell that possesses additional genetic alterations.
The tumor that eventually arises, whether it is a conventional
Ewing’s sarcoma, an unusual variant, a biphenotypic tumor,
lymphoblastic leukemia, or some other disease, will probably
depend upon an interplay between the cellular background
in which it arises and the set of cooperating mutations that
occur.
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